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Cyclophosphamide and tamoxifen as adjuvant therapies in the
management of breast cancer
Preliminary Analysis by the CRC Adjuvant Breast Trial Working Party*
Summary In 1980 the Cancer Research Campaign launched a multi-centre breast cancer trial; aimed at
repeating the Scandinavian Chemotherapy Study Group's cyclophosphamide trial, and the NATO tamoxifen
study; thereby further evaluating the role of these two adjuvant regimens in patients with early breast cancer.
Two thousand two hundred and thirty women were randomized into this trial between 1980 and 1985 and
preliminary analyses demonstrate a significant improvement in event-free survival for both regimens. Results
from this study closely parallel the two trials it set out to repeat.
Although one woman in twelve will develop breast cancer in
her lifetime very few of these will be entered into a
prospective randomized clinical trial (Tate et al., 1979),
despite there still being much uncertainty about the best
treatment for the disease. In order to detect small but
nevertheless clinically worthwhile differences large trials are
needed. Many patients must therefore be recruited over a
relatively short time period. This requires the cooperation of
many clinicians not only in large teaching hospitals with
Specialist Units but also in the District General Hospital
where the number of eligible patients may be relatively small
but where the majority of patients in this country are
nevertheless treated. For this reason the trial protocols must
address pertinent questions and be easy to implement in
busy surgical departments which do not have the advantages
of Specialist Oncology Services.
The CRC Adjuvant Breast Trial which was launched in
1981 was designed to fulfill these criteria. The aim of this
study was to replicate the cyclophosphamide trial of the
Scandinavian Adjuvant Chemotherapy Study Group (Nissen-
Meyer et al., 1982), and the NATO tamoxifen study (NATO,
1983). These trials were set up in 1965 and 1977 respectively
to address questions relating to 'soft option' adjuvant sys-
temic therapy, and both subsequently described an improve-
ment in disease-free and overall survival (NATO, 1983;
Nissen-Meyer et al., 1978). The Scandinavian trial incorpor-
ated a 6 day perioperative course of cyclophosphamide and
with a follow-up of more than 15 years has shown an
increase in both disease-free and overall survival for patients
given this low toxicity regimen; very few other trials have
investigated perioperative chemotherapy (Houghton et al.,
1987).
Materials and methods
Two thousand two hundred and thirty women under 75
years of age, with stage I or II breast cancer (Tl or 2, NO
or 1, MO) were entered into the trial between September
1980 and December 1985. Following primary treatment
patients were randomized centrally, into one of 4 treatment
groups:- (a) control no further therapy, (b) tamoxifen
10mgbd for 2 years, (c) cyclophosphamide 30mgkg-1 body
wt (maximum 2400mg) i.v. for 6 days post-operatively with
approximately 5mgkg-' daily in one i.v. injection or (d)
combination - tamoxifen and cyclophosphamide at the pre-
stated doses.
Primary therapy was either total mastectomy with axillary
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sampling and radiotherapy for node positive cases, or total
mastectomy with axillary clearance and no radiotherapy. In
1983 a third option was offered, local excision with axillary
sampling and radiotherapy. Individual clinicians were asked
to nominate their choice of primary therapy and to treat all
patients in the same way. Radiotherapy was given by ortho-
or super-voltage according to local practice.
The trial utilized a 2 x 2 factorial design, allowing two
separate questions to be addressed simultaneously.
All patients were followed up regularly by clinical examin-
ation and data forms were forwarded to the Trials Centre on
each occasion. All data received at the Trials Centre under-
went control checks for accuracy and completeness.
Results
With a median follow-up of 3 years and 4 months, 'main
effects' analyses have been performed (i.e., independent
assessment of tamoxifen and cyclophosphamide therapy with
their appropriate control groups), for both event-free and
overall survival. An event-free survival analysis includes all
patients who have had an 'event', this includes not only
those who have relapsed, but also those who have developed
a second primary, and those for whom death occurred as a
first event.
Tamoxifen main effects
From 1st May 1984 following data published by the NATO
(1983) tamoxifen trial clinicians were given the option to
prescribe tamoxifen for all patients, with randomization only
into the cyclophosphamide part of the trial. Therefore, only
1912 patients were eligible for this analysis. Comparison of
the 2 groups (those receiving adjuvant tamoxifen or not)
showed they were well balanced with respect to known
prognostic variables (Table I).
A total of 589 patients have experienced an 'event'
(recurrent disease, new primary tumour or death without
recurrence). Significantly fewer have been observed in the
tamoxifen treated group (tam =246, control =343, overall
adjusted logrank X2 =23.29, P<0.001; Figure 1). The
beneficial effect is evident in all tamoxifen treated subgroups
when stratified by menstrual or nodal status (Table II), it is
from these strata that the overall adjusted x2 has been
calculated.
The incidence of new contralateral breast carcinomas was
significantly reduced in the tamoxifen group (tam=7,
control= 18, logrank X2=5.39, P=0.02).
Despite an advantage being seen in favour of the tamoxi-
fen group with regard to time to first event, this has not
been translated into a survival benefit, although there is a
trend in the same direction (tam= 166, control = 194, logrank
X2= 1.63, P=0.20; deaths from all causes).
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100- Table I Comparison of treatment groups - tamoxifen
Control (%) Tamoxifen (%)
No of patients 965 (50.5) 947 (49.5)
Mean age (yrs) 55.4 54.8
Path. tumour (<2cm) 267 (27.7) 268 (28.3)
Node positive 372 (38.5) 401 (42.3)
Premenopausal 262 (27.2) 281 (29.8)
80-
a)
CD 60-
a)
w 40-
20- Table II Tamoxifen - analysis of all events (a) overall and
(b) by menopausal and nodal status
Events
Treatment
(a) Overall analysis
Tamoxifen
Control
No. Observed Expected OIE
947 246 300.07 0.82
965 343 288.93 1.19
(b) Analysis by menstrual and nodal status
1. Premenopausal, node negative
Tamoxifen 208 35
Control 108 53
2. Premenopausal, node positive
Tamoxifen 140 66
Control 130 68
3. Postmenopausal, node negative
Tamoxifen 257 34
Control 314 74
4. Postmenopausal, node positive
Tamoxifen 232 84
Control 216 108
47.23 0.74
40.77 1.30
- - - - - - - Tamoxifen
Control
x2 =23.29
P < 0.01
Numbers at risk
947 879 750
965 864 718
567 391 163 Tamoxifen
523 347 151 Control
0 1 2 3 4 5
Time (years)
Figure 1 Tamoxifen main effects analysis - First event. In this
and subsequent figures the 'numbers at risk' represent the
number of patients event-free at entry and annually thereafter.
This number decreases in the latter years since there are fewer
patients with relevant times.
100-
71.26 0.93
62.74 1.08
49.61 0.69
58.39 1.27
104.42 0.80
87.58 1.23
observed no. ofevents
O/E = If < 1.0 benefit for that group.
expected no. ofevents
Cyclophosphamide main effects
All 2230 patients entered into the trial were included in this
comparison and treated and control groups were well
matched for patient characteristics and prognostic factors.
The commonest reported side-effects of treatment were alo-
pecia (43% patients overall in the 3 months following the
course) with 20% of these requiring a wig, and nausea (20%
patients). Severe leucopenia was reported in 6.8% patients at
14 days. Despite this toxicity the therapy was relatively well
tolerated as indicated by the fact that of the patients
allocated to receive cyclophosphamide (1139) 91.3% (1040)
completed the six day course.
At the time of the analysis 638 patients have been
recorded as having an event (recurrent disease, new primary
tumour or death without recurrence). Significantly fewer
events have been observed in the cyclophosphamide group
(cyclo =307, control =331, overall adjusted logrank
-2=4.01, P=0.045; Figure 2). When stratified by menstrual
and nodal status this beneficial effect is demonstrated in all
but the premenopausal node positive subgroup (Table III).
The overall adjusted x2 has been calculated from the strata.
Currently no significant effect of cyclophosphamide on
overall survival is seen. A total of 386 deaths have been
recorded (cyclo=185, control=201, X2=1.49, P=0.22).
Cox's regression analysis and treatment interactions
A Cox regression analysis was performed on first event rates;
nodal status, tumour size and tamoxifen therapy were found
to be important predictors of time to first event. There was
also a suggestion that cyclophosphamide therapy may be of
importance. No significant interactions between any of these
factors were found. The lack of interaction between the two
treatments is confirmed upon subgroup analysis. A four way
(2 x 2) randomization such as this lends itself to six different
comparisons (Table IV). When examining all of these possi-
bilities it is necessary to make a correction for multiple
comparisons, e.g. a Bonferoni statistic which requires a
80-
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- 60-
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- -== - - - - - Cyclo
Control
x2 =4.01
P < 0.045
Numbers at risk
1139 1052 829 556 376 155 Cyclo
1091 979 765 534 362 159 Control
0 1 2 3 4 5
Time (years)
Figure 2 Cyclophosphamide main effects analysis - First event.
Table III Cyclophosphamide - analysis of all events (a) overall and
(b) by menopausal and nodal status
Events
Treatment
(a) Overall analysis
Cyclophosphamide
Control
No. Observed Expected OIE
1139 307 329.11 0.93
1091 331 308.89 1.07
(b) Analysis by menstrual and nodal status
1. Premenopausal, node negative
Cyclophosphamide 238
Control 229
2. Premenopausal, node positive
Cyclophosphamide 157
Control 167
3. Postmenopausal, node negative
Cyclophosphamide 353
Control 317
4. Postmenopausal, node positive
Cyclophosphamide 275 1
Control 243 1
46 49.58 0.93
50 46.42 1.08
70 69.89 1.00
74 74.11 1.00
52 63.82 0.81
67 55.18 1.21
103
104
110.89 0.93
96.11 1.08
observed no. ofevents
O/E = If < 1.0 benefit for that group. expected no. ofevents
Table IV Four group comparison - using the Bonferoni statistic
TAM
CYCLO
CYCLO+TAM
11.90
P<0.01
2.45
NS
19.18
P<0.001
4.40
NS
for significance
x2 >7.00
P<0.05
0.68 8.93
NS P<0.005
CONTROL TAM CYCLO
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Numbers at risk
493 463
483 427
0
394
356
365
353
295
272
261
262 176
78 Tam + cyclo
64 Tamoxifen
80 Cyclo
74 Control
1 2 3 4 5
Time (years)
Figure 3 Four group analysis - First event.
x2>7 for significance, rather than the usual value of
x 2>3.84. Figure 3 illustrates the event-free survival in each
of the four groups of patients in life-table format.
Analysis of survival time by Cox's multiple regression
analysis demonstrated that nodal status was important, but
no other variables were found to be of predictive value.
Discussion
The results from the CRC Adjuvant Breast Trial are very
similar to those obtained in the two earlier trials at a similar
point of follow-up.
Analysis of the tamoxifen main effect has shown an
improvement in event-free survival for both pre- and post-
menopausal patients receiving tamoxifen. The latter is con-
sistent with many other tamoxifen trials - the majority of
which only recruited postmenopausal patients (NATO, 1985;
Wilson et al., 1985; Palshof, 1981; Ribeiro & Palmer, 1983;
Wallgren et al., 1983; Rose et al., 1983; Pritchard et al., 1984;
Scottish Cancer Trials Office, 1987). However the CRC
Adjuvant Breast Trial was also open to premenopausal
patients, irrespective of nodal status and there was a signifi-
cant benefit in this subgroup for those who received tamoxi-
fen, similar to that described by the Scottish trial. Multiple
regression analysis also failed to demonstrate any inter-
actions, supporting the view that tamoxifen was having
similar effects in all subgroups. The recent World Overview
of tamoxifen trials (Anonymous, 1984; BCTCS/UICC/WHO,
1985) showed no benefit of tamoxifen in the premenopausal
group, but this may be due to the relatively low numbers of
patients and short follow-up interval. In addition the major-
ity also received systemic adjuvant chemotherapy which may
have pre-empted the tamoxifen effect via a chemical
castration.
As yet a survival advantage for adjuvant tamoxifen has
not emerged within this trial. There are three possible
explanations for this. Firstly, that the estimate of survival
advantage in trials previously reported was exaggerated as a
result of random bias. Secondly, that insufficient deaths have
occurred to detect a 20-30% reduction in the five year
m'ortality rates or, thirdly, that the follow-up has been
insufficient to allow that group of patients with an excess of
distant metastases in the control group to experience the
lethality of those events. Referring back to the statistical
overview of adjuvant tamoxifen trials, the second and third
explanations are the most likely.
Results obtained in the cyclophosphamide comparison are
also showing a significant benefit in favour of the treated
group. Despite a similar benefit first reported by the
SACSG, this regimen has not been incorporated into general
clinical practice. The results reported now support those
previously obtained (Nissen-Meyer et al., 1986, 1987), and
although the benefit may be small it could be clinically
worthwhile. However, with the data from the overview
showing a significant benefit for patients under 50 years
given prolonged adjuvant chemotherapy, the exact place of
perioperative cyclophosphamide therapy in the treatment of
early breast cancer has still to be defined, and long-term
follow-up is required. The regimen is much less toxic than
cyclical polychemotherapy and it may therefore be of
importance for patients either not fit for or not willing to
undergo the more complex treatment schedules, or for those
treated in Units without access to the expertise of a Medical
Oncologist.
Inspection of the life table for event free survival within
the four therapeutic sub-groups of the trial (Figure 3) gives
an impression of a rank order of benefit. Great caution has
to be recommended not to over-interpret what appears to be
a tidy and intuitively satisfying result. As already described
above, the Cox's Regression Analysis for sub-group compari-
sons fails to show any significant treatment interactions.
However, with nearly 500 patients in each arm there is a
reasonable chance that, in the long term, we might be able
to answer the question as to whether the benefit of cyclo-
phosphamide and tamoxifen treatment are additive, synergis-
tic or antagonistic when given together.
In conclusion, at a median follow-up of approximately
three years the CRC Adjuvant Trial has demonstrated that a
six day course of perioperative cyclophosphamide or two
years of tamoxifen, significantly improves the event-free
survival. These results closely mirror those obtained by the
Scandinavian and NATO groups.
Perhaps the most important new observations within this
study are the suggestion that adjuvant tamoxifen can prevent
the development of a new contralateral primary and that its
benefits are equally felt amongst the premenopausal as
well as the postmenopausal patients irrespective of nodal
status. So far there is no evidence that the addition of long-
term tamoxifen to perioperative cyclophosphamide produces
a greater benefit than either agent given alone.
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